| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$88 |
Market Update - Record First-Half FY25 Results
|
29 Jul 2025 8:53AM |
$0.430 |
$0.705 |
risen by
63.95%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- EDU Holdings Limited recorded strong financial and operational results for the first half of FY25.
- Revenue and EBITDA reached record highs compared to previous periods.
- Student enrolments grew significantly, particularly in health and community services programs.
- Continued strategic investment in course expansion and campus infrastructure.
- Focus on student support, operational efficiency, and geographic diversification.
- Positive outlook maintained for the remainder of the fiscal year.
- Commitment to delivering quality education and supporting student outcomes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$206 |
Investor Presentation
|
29 Jul 2025 8:52AM |
$0.580 |
$0.595 |
risen by
2.59%
|
|
| Solis Minerals Ltd (SLM) ORDINARY FULLY PAID |
Materials |
$9 |
Geophysics Defines Compelling Cu-Au Targets at Cinto
|
29 Jul 2025 8:52AM |
$0.080 |
$0.033 |
fallen by
58.75%
|
|
SLM - Price-sensitive ASX Announcement
Full Release
Key Points
- Solis Minerals Ltd completed a ground geophysical survey at the Cinto Project in Peru.
- The survey identified strong chargeability and resistivity anomalies, indicating possible sulphide mineralization.
- These anomalies are interpreted as potential copper-gold porphyry targets.
- The geophysical results align with areas of historical artisanal mining and surface geochemical anomalies.
- The defined targets will be tested by drilling to assess their mineralization potential.
- The announcement underscores the technical approach and exploration strategy of Solis Minerals Ltd at Cinto.
- The project highlights the ongoing commitment of Solis Minerals Ltd to copper-gold exploration in Peru.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$53 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 8:51AM |
$0.083 |
$0.077 |
fallen by
7.23%
|
|
CCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly cash receipts from customers totaled $3.3 million, reflecting ongoing revenue growth.
- Change Financial completed its Mastercard principal issuer and acquirer licence, expanding capabilities.
- The company continued to focus on scaling its payments and card solutions offering, especially in Australia and New Zealand.
- New client contracts and technology integration progressed during the quarter.
- Prudent cost management strategies remained in place to support business sustainability.
- The cash flow report includes details of operating, investing, and financing activities.
- Change Financial indicated it has sufficient funding for its future operational needs.
- The report provides a summary of related party transactions for the quarter.
- Ongoing focus on product innovation and business development to drive growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana Private Equity Trust (PE1) ORDINARY UNITS FULLY PAID |
Financials |
$396 |
Update - Notification of buy-back - PE1
|
29 Jul 2025 8:50AM |
$1.300 |
$1.480 |
risen by
13.85%
|
|
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$206 |
June 2025 Quarterly Report and Appendix 4C
|
29 Jul 2025 8:50AM |
$0.580 |
$0.595 |
risen by
2.59%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly cash flow report with receipts from customers and operational expenditures
- Updates on strategic initiatives and clinical studies
- Progress in product development and commercial performance
- Business development activities and regulatory updates provided
- Appendix 4C included as per ASX listing requirements
- Emphasis on continued growth and innovation in biosurgery solutions
- Discussion of future outlook and strategic priorities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Osmond Resources Limited (OSM) ORDINARY FULLY PAID |
Materials |
$66 |
Osmond Confirms Orion Investigation Permit Award
|
29 Jul 2025 8:50AM |
$0.825 |
$0.480 |
fallen by
41.82%
|
|
OSM - Price-sensitive ASX Announcement
Full Release
Key Points
- Osmond Resources Limited (OSM) has been awarded the Investigation Permit (EL00015) for the Orion Project.
- The Orion Project is located on the Yorke Peninsula in South Australia, approximately 40km west-northwest of Minlaton.
- The permit area covers 1,238 square kilometers and is considered prospective for IOCG and sediment-hosted copper mineralisation.
- The permit was granted by the South Australian Department for Energy and Mining and is valid for five years.
- Osmond plans to conduct exploration activities including geophysical surveys and drilling within the permit area.
- The Orion Project is viewed as strategically important within Osmond's exploration portfolio.
- The company is optimistic about the mineralisation potential within the newly permitted area.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Greatland Resources Limited (GGP) ORDINARY FULLY PAID |
Materials |
$7,631 |
June 2025 Quarterly Activities Report
|
29 Jul 2025 8:49AM |
$6.890 |
$11.340 |
risen by
64.59%
|
|
GGP - Price-sensitive ASX Announcement
Full Release
Key Points
- Produced 78,283 oz Au and 3,729t Cu with AISC of $1,736/oz Au.
- Key drill results show promising Au & Cu mineralization at Main Dome and West Dome.
- Sold 87,529 oz Au and 3,740t Cu at A$5,014/oz Au and A$12,718/t Cu.
- Net revenue for the quarter was A$487 million.
- Strong potential for future exploration and mining at key sites.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spacetalk Ltd (SPA) ORDINARY FULLY PAID |
Information Technology |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 8:48AM |
$0.150 |
$0.064 |
fallen by
57.33%
|
|
SPA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers activities and cash flow for the period ending 31 March 2024.
- Growth in device sales and active subscribers, especially in international markets.
- Operational expenditure reduced as a result of cost-saving measures.
- Continued focus on product development and innovation.
- Expansion of global distribution and retail partnerships, particularly in the UK and Europe.
- Strengthening of brand presence and marketing initiatives.
- Disciplined cash management maintained a stable financial position.
- Plans for upcoming product launches and further market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| One Click Group Limited (1CG) ORDINARY FULLY PAID |
Industrials |
$12 |
One Click Life Surpasses 200,000 Registered Users
|
29 Jul 2025 8:48AM |
$0.009 |
$0.009 |
fallen by
0%
|
|
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$34 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 8:47AM |
$0.145 |
$0.120 |
fallen by
17.24%
|
|
EYE - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers activities for the period ending 31 March 2024.
- Nova Eye Medical Limited experienced increased sales momentum, particularly in North America.
- The company invested in expanding its direct sales team and clinical support.
- Progress was made with multi-center clinical studies for glaucoma treatment technologies.
- Revenue growth was recorded compared to the previous corresponding period.
- Continued strategic focus on product development and regulatory approvals.
- Cost-saving initiatives were implemented during the period.
- The company maintained a strong cash position at the end of the quarter.
- Detailed Appendix 4C Cash Flow Report provided, including receipts, expenditures, and R&D costs.
- Forecast of cash outflows for the next quarter was included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$88 |
ALG T3'25 enrolments - up 2% on PCP
|
29 Jul 2025 8:47AM |
$0.430 |
$0.705 |
risen by
63.95%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- ALG T3'25 enrolments up 2% on the prior corresponding period (PCP)
- Positive enrolment growth demonstrates stability and demand for courses
- EDU Holdings Limited maintains a focus on operational and strategic improvements
- Management reiterates commitment to student recruitment and retention initiatives
- Announcement underscores company’s efforts to support long-term growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sky Metals Limited (SKY) ORDINARY FULLY PAID |
Materials |
$133 |
Trading Halt
|
29 Jul 2025 8:45AM |
$0.071 |
$0.135 |
risen by
90.14%
|
|
SKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Sky Metals Limited requested a trading halt on 11 June 2024.
- The trading halt is due to a proposed capital raising.
- The trading halt will remain until an announcement is made or trading resumes on 13 June 2024.
- The company submitted the request to the ASX.
- Sky Metals Limited is not aware of any reason the trading halt should not be granted.
- No further information is required to be disclosed at this stage.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Terramin Australia Limited (TZN) ORDINARY FULLY PAID |
Materials |
$76 |
June 2025 Quarterly Activities Report and Appendix 5B
|
29 Jul 2025 8:45AM |
$0.051 |
$0.032 |
fallen by
37.25%
|
|
TZN - Price-sensitive ASX Announcement
Full Release
Key Points
- Continued engagement with the South Australian Government to progress the Bird-in-Hand Gold Project, focusing on permitting and environmental studies.
- Ongoing remediation activities at the Angas Zinc Mine, with efforts to ensure compliance with regulatory and environmental requirements.
- Active negotiations with Algerian authorities and stakeholders concerning the advancement of the Tala Hamza Zinc Project.
- Financial summary provided through Appendix 5B, including cash position, operational expenditures, and project-related spending.
- Strategic review of existing assets and evaluation of future growth opportunities within Australia and overseas.
- Commitment to environmental management, regulatory compliance, and community engagement across all project sites.
- Forward outlook highlights continued focus on permitting, project development, and cost management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| New World Resources Limited (NWC) ORDINARY FULLY PAID |
Materials |
- |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jul 2025 8:45AM |
$0.067 |
$0.067 |
fallen by
0%
|
|
NWC - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarter covers activities to 31 March 2023.
- Ongoing exploration and drilling at Antler Copper Project in Arizona.
- Completion of significant infill and extensional drilling programs.
- Advancements in permitting, regulatory submissions, and project infrastructure planning.
- Project financing and stakeholder engagement activities continued.
- Detailed cash flow analysis included, covering exploration, evaluation, and administration expenses.
- End-of-quarter cash position reported.
- No mining production or development revenue received during the quarter.
- Expenditure on exploration and evaluation was the major outflow.
- Appendix 5B included as required under ASX Listing Rules.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,749 |
Appendix 3C
|
29 Jul 2025 8:44AM |
$51.910 |
$41.610 |
fallen by
19.84%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,749 |
Appendix 3C
|
29 Jul 2025 8:43AM |
$51.910 |
$41.610 |
fallen by
19.84%
|
|
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$75 |
Quarterly Activities & Cashflow Report
|
29 Jul 2025 8:42AM |
$0.615 |
$0.330 |
fallen by
46.34%
|
|
BIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Biome Australia Limited reported record quarterly revenue for Q3 FY24.
- Revenue growth was attributed to strong demand, new product launches, and expanded distribution.
- The company onboarded new wholesale customers and invested strategically in marketing.
- Operational focus included cost control, gross margin improvement, and cash position reinforcement.
- Biome Australia launched innovative products, contributing to growth.
- Investments were made in inventory and marketing to support future sales.
- Cashflow from operating activities was negatively impacted by higher inventory purchases.
- The company maintained a strong outlook for continued growth in future quarters.
- Biome Australia reaffirmed its commitment to shareholder value through further market penetration and product innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$74 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 8:41AM |
$0.370 |
$0.405 |
risen by
9.46%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Ltd progressed clinical and commercial strategies for SPONTAN®, an orodispersible film for erectile dysfunction.
- The company prepared for a clinical trial in Australia, including investigator engagement and recruitment programs.
- Expansion of commercialisation strategy and partnerships were highlighted during the quarter.
- LTR Pharma continued regulatory, manufacturing, and intellectual property initiatives for SPONTAN®.
- Financial overview showed net operating cash outflows but a solid end-of-quarter cash balance.
- Company confirmed sufficient funds are available for the execution of near-term milestones.
- Appendix 4C included details about cash flows and expenditure breakdown for the quarter ending 31 March 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$31 |
Quarterly Activities Report /Appendix 4C Cash Flow Statement
|
29 Jul 2025 8:40AM |
$0.006 |
$0.018 |
risen by
200%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- 1AI (Algorae Pharmaceuticals Limited) reported continued progress in AI-driven drug discovery and development projects.
- The company highlighted strategic partnerships and collaborations formed during the quarter to enhance research capabilities.
- Operational updates included advancements in the proprietary AI platform and research pipelines.
- The Appendix 4C Cash Flow Statement detailed receipts, payments, and net cash outflows for the period.
- Cash at the end of the period was reported, outlining the company's liquidity position.
- Risks, regulatory compliance, and future growth opportunities were discussed.
- Management provided commentary on business direction and upcoming objectives for the next quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WIA Gold Limited (WIA) ORDINARY FULLY PAID |
Materials |
$606 |
Quarterly Activities and Cashflow Report - June 2025
|
29 Jul 2025 8:40AM |
$0.285 |
$0.410 |
risen by
43.86%
|
|
WIA - Price-sensitive ASX Announcement
Full Release
Key Points
- Substantial progress achieved at Kokoseb Gold Discovery in Namibia, including successful drilling and resource extension.
- Regional exploration programs continued with systematic sampling and drilling, yielding encouraging results.
- Assay results confirmed high-grade gold intersections, supporting the potential for resource expansion.
- The company maintains a disciplined financial approach, with clear reporting on expenditures and cash balance.
- Corporate activities included community engagement and maintaining strong local partnerships.
- Future plans focus on further drilling, resource definition, and advancing key project milestones.
- The quarterly report demonstrates WIA Gold Limited’s commitment to sustainable exploration and value creation for shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EMvision Medical Devices Limited (EMV) ORDINARY FULLY PAID |
Health Care |
$147 |
First Responder Program Advanced & Grant Milestone Achieved
|
29 Jul 2025 8:40AM |
$1.795 |
$1.580 |
fallen by
11.98%
|
|
EMV - Price-sensitive ASX Announcement
Full Release
Key Points
- EMvision Medical Devices Limited achieved an advanced milestone in its First Responder Program.
- The company secured a grant milestone, providing additional funding for development.
- EMvision’s portable brain imaging device is designed for pre-hospital and first responder environments.
- The technology targets rapid diagnosis of stroke and brain injuries in emergency settings.
- Progress includes technical development, clinical validation, and stakeholder collaboration.
- Secured funding will support further research, development, and regulatory activities.
- The initiative aligns with health sector priorities and seeks to address unmet clinical needs.
- EMvision outlines ongoing commercialization and regulatory pathways for the device.
- The announcement highlights the technology’s potential to improve patient outcomes and system efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Powerhouse Ventures Limited (PVL) ORDINARY FULLY PAID |
Financials |
$19 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 8:40AM |
$0.090 |
$0.115 |
risen by
27.78%
|
|
PVL - Price-sensitive ASX Announcement
Full Release
Key Points
- PVL released its Quarterly Activities Report and Appendix 4C for the quarter ending 31 March 2023.
- Active management of investment portfolio and support for investee companies remained a focus.
- No new major investments were made during the quarter.
- Net cash outflow was primarily due to operating and corporate costs.
- Cash and cash equivalents were maintained at quarter-end.
- Ongoing monitoring and management of liquidity and operational expenses.
- Updates were provided on key portfolio companies and investment status.
- Future strategy remains focused on prudent cash management and shareholder value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Freelancer Limited (FLN) ORDINARY FULLY PAID |
Industrials |
$70 |
1H25 Results Presentation
|
29 Jul 2025 8:39AM |
$0.280 |
$0.155 |
fallen by
44.64%
|
|
FLN - Price-sensitive ASX Announcement
Full Release
Key Points
- Freelancer Limited presented its financial and operational results for 1H25, covering the half-year ending 31 December 2023.
- The company recorded improvements in profitability, with gross margins rising and operating costs being significantly reduced.
- Freelancer.com, Escrow.com, and Freightlancer remain the core business segments, each showing resilience despite difficult macroeconomic conditions.
- Investments in AI-driven product features and innovation are a key priority, with several new initiatives underway.
- The company is expanding its enterprise and government business, leveraging its platform to secure larger, high-value contracts.
- Cost-saving measures, including staff reductions and operational streamlining, contributed to improved EBITDA.
- Freelancer maintains a strong balance sheet, with no debt and a healthy cash position.
- Management remains focused on long-term growth opportunities, especially in international markets and new product offerings.
- The business is actively responding to global economic pressures through prudent financial management and strategic repositioning.
- The document includes forward-looking statements regarding continued investment in technology and market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vitrafy Life Sciences Limited (VFY) ORDINARY FULLY PAID |
Health Care |
$68 |
Appendix 4C, FY25 Annual Results and Investor Call Schedule
|
29 Jul 2025 8:38AM |
$1.620 |
$1.680 |
risen by
3.70%
|
|
Call 1300 880 160
Start a chat
Schedule a call
